Hengray Pharmaceutical announced that it has entered into an agreement with Dr. Reddy's Laborato
더 읽어보세요 2023-10-09뉴스 목록
155 million dollars! Hengrui Medicine has another innovative drug to go to sea
Bagel Biologics receives approval to initiate Phase I clinical trial of TCR cell therapy
On September 9, 2023, Biosyngen Pte Ltd (hereinafter referred to as "Biosyngen") announced
더 읽어보세요 2023-09-13
Researchers at Zhejiang University School of Medicine have revealed that the concept of targeting DDK can improve the efficacy of immunotherapy for liver cancer
Hepatocellular carcinoma is a common and highly aggressive tumor that has been recognized as the sev
더 읽어보세요 2023-08-29
On July 14, Bojian's listing application for tofersen injection was accepted.
On April 25, 2023, the FDA accelerated approval of the antisense oligonucleotide therapy tofersen (Q
더 읽어보세요 2023-07-30
The annual bleeding rate of patients was reduced by 71%, and Pfizer's marketing application for hemophilia gene therapy was accepted by the FDA
Pfizer, Inc. (NYSE: PFE) today announced that the FDA has accepted a biologics license application (
더 읽어보세요 2023-07-03
FDA approves First repeatable drug gene Therapy, $630,000 a Year, for 'most painful diseases'
On May 19, 2023, the FDA approved Beremagene Geperpavec (B-VEC), a topical gene therapy based on the
더 읽어보세요 2023-05-22
Wang Ben's team at Zhejiang University developed fluorine-containing polymer assembly drugs to achieve chemotherapeutic-immune cascade cancer therapy
Recently, Wang's research group from the Institute of Translational Medicine of Zhejiang Univers
더 읽어보세요 2023-04-23
The first patient administration of the new NASH drug, Kylo-0603, was completed in Phase I in China
On March 28, 2023, Kylo-0603, a thyroxine receptor-β (THR-β) agonist drug independently developed by
더 읽어보세요 2023-04-09
China's first personalized tumor newborn antigen vaccine has been approved by NMPA to enter the clinical stage
On March 15, 2023, the website of the Center for Drug Review and Evaluation (CDE) of the State Medic
더 읽어보세요 2023-03-16
The world's second! FDA grants Pfizer priority review for CD3/BCMA bispecies
Pfizer announced that the U.S. Food and Drug Administration (FDA) has granted priority review status
더 읽어보세요 2023-02-23